Characterization of the pathogenic autoreactive T cells in cyclosporine-induced syngeneic graft-versus-host disease

被引:0
|
作者
Chen, WR [1 ]
Thoburn, C [1 ]
Hess, AD [1 ]
机构
[1] Johns Hopkins Univ, Ctr Oncol, Div Immunol & Hematopoiesis, Baltimore, MD 21287 USA
来源
JOURNAL OF IMMUNOLOGY | 1998年 / 161卷 / 12期
关键词
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Administration of the immunosuppressive drug cyclosporine after syngeneic bone marrow transplantation paradoxically elicits a systemic autoimmune syndrome resembling graft-vs-host disease (GVHD), This syndrome, termed syngeneic GVHD, is associated with the development of CD8(+) cytolytic T lymphocytes that promiscuously recognize NHC class II molecules in association with a peptide from the invariant chain (CLIP), Clonal analysis reveals a major subset of cells that are pathogenic and require the N-terminial flanking region of CLIP for activation, while there is a minor subset of nonpathogenic T cells that require the C-terminal flanking region. The present studies show that pathogenic T cells produce type 1 cytokines (IL-2; IFN-gamma), while the nonpathogenic clones produce type 2 cytokines (IL-4; IL-IO), Moreover, the repertoire of the pathogenic T cells is highly conserved with respect to V beta and V alpha TCR gene expression. The vast majority of clones express V beta 8.5 (12/12) and V alpha 11l (11/12). Although a limited number was evaluated, the nonpathogenic clones have only a V alpha restriction. Sequence analysis of the pathogenic T cell clones reveals a marked heterogeneity in the complementarity-determining region 3 domain and differential J region gene expression for both TCR alpha- and beta-chains, Evaluation of the specificity of these clones suggests that the functional interaction between the N-terminal flanking region of CUP (defined by the amino acid sequence -KPVSP-) and the V region of the TCR is critical, allowing effective target cell recognition and tissue destruction in syngeneic GVHD.
引用
收藏
页码:7040 / 7046
页数:7
相关论文
共 50 条
  • [31] T cells of recipient origin mediate the development of murine syngeneic graft-versus-host disease
    Brandon, JA
    Jennings, CD
    Caywood, BE
    Perez, J
    Kaplan, AM
    Bryson, JS
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 71 - 71
  • [32] STUDIES ON THE IMMUNOBIOLOGY OF SYNGENEIC AND AUTOLOGOUS GRAFT-VERSUS-HOST DISEASE IN CYCLOSPORINE-TREATED RATS
    GLAZIER, A
    TUTSCHKA, PJ
    FARMER, E
    TRANSPLANTATION PROCEEDINGS, 1983, 15 (04) : 3035 - 3041
  • [33] Regulatory T cells in graft-versus-host disease
    Salomon, Benoit L.
    Sudres, Muriel
    Cohen, Jose L.
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2006, 28 (01): : 25 - 29
  • [34] Recipient γδ T cells in graft-versus-host disease
    Anderson, BE
    Shlomchik, WD
    Shlomchik, MJ
    BLOOD, 2006, 107 (09) : 3808 - 3809
  • [35] Regulatory T cells in graft-versus-host disease
    Benoît L. Salomon
    Muriel Sudres
    José L. Cohen
    Springer Seminars in Immunopathology, 2006, 28 : 25 - 29
  • [36] Regulatory T Cells in Graft-versus-Host Disease
    Masuda, Shigeo
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10): : 962 - 962
  • [37] Induction of murine syngeneic graft-versus-host disease by cells of recipient origin
    Brandon, J. Anthony
    Jennings, C. Darrell
    Perez, Jacqueline
    Caywood, Betty
    Alapat, Daisy
    Kaplan, Alan M.
    Bryson, J. Scott
    TRANSPLANTATION, 2007, 83 (12) : 1620 - 1627
  • [38] CYCLOSPORINE-INDUCED PSEUDO-GRAFT-VERSUS-HOST DISEASE IN THE EARLY POST-CYCLOSPORINE PERIOD
    BESCHORNER, WE
    SHINN, CA
    FISCHER, AC
    SANTOS, GW
    HESS, AD
    TRANSPLANTATION, 1988, 46 (02) : S112 - S117
  • [39] SYNGENEIC GRAFT-VERSUS-HOST DISEASE (SGVHD) - A MODEL FOR AUTOIMMUNITY
    KAPLAN, AM
    BRYSON, JS
    JOURNAL OF LEUKOCYTE BIOLOGY, 1993, : 76 - 76
  • [40] Prophylaxis of graft-versus-host disease with cyclosporine–prednisone is associated with increased risk of chronic graft-versus-host disease
    S Kumar
    MG Chen
    DA Gastineau
    MA Gertz
    DJ Inwards
    MQ Lacy
    A Tefferi
    WS Harmsen
    MR Litzow
    Bone Marrow Transplantation, 2001, 27 : 1133 - 1140